2026 Outlook: CDMO Market for Injectables

Sponsored by Lonza AG

Ian Tzeng, Managing Director and Partner, L.E.K. Consulting

In taking a 360-degree view of the CDMO market for injectables, what are the key developments from 2025 that continue to loom large in 2026? Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and lead of L.E.K.’s Pharmaceutical Contract Services Practice, provided perspectives on evolving US tariff/trade policy, a policy movement in the US to most-favored nation drug pricing, and key technology trends and what impact they may have on the CDMO market for injectables.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

For a full list of the 2026 podcast episode schedule, click here.

You May Also Like

Beyond ADCs: Next-Generation Drug Conjugates

By
Sponsored by Lonza AG Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative to antibody drug conjugates (ADCs),…

New Excipient Products: Are They Coming?

By
Innovation in excipients is important to optimize a drug formulation, but there are barriers to innovation, including regulatory barriers, which excipient manufacturers and users are seeking to address. Providing the…

Pipeline Potential: Small-Molecule Drugs

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…

CDMO Outlook: Small Molecules—What Lies Ahead?

By
Sponsored by Vetter As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well…